NCT02978625 2026-03-18
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
Abramson Cancer Center at Penn Medicine
Prescient Therapeutics, Ltd.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center